You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BCMA expressing Lymphomas

Showing 1 - 25 of 1,555
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

Completed
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 3, 2022

Kidney Cancer, Lymphomas, Positron Emission Tomography Trial in Shanghai ([18F]RCCB6 PET Imaging)

Recruiting
  • Kidney Cancer
  • +2 more
  • [18F]RCCB6 PET Imaging
  • Shanghai, China
    Huashan Hospital
Nov 19, 2023

CS1+ or BCMA+ Multiple Myeloma Trial in Wuhan (Conditioning chemo followed by CAR T cell infusion)

Recruiting
  • CS1+ or BCMA+ Multiple Myeloma
  • Conditioning chemotherapy followed by CAR T cell infusion
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Feb 11, 2022

Multiple Myeloma Trial in Bethesda, Oklahoma City, Fairfax (Descartes-08, Fludarabine, Cyclophosphamide)

Completed
  • Multiple Myeloma
  • Descartes-08
  • +2 more
  • Bethesda, Maryland
  • +2 more
Mar 10, 2022

Multiple Myeloma Trial in Shanghai (Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Multiple Myeloma
  • Anti-BCMA CAR-T cells
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 29, 2021

T Cell Lymphoma Trial in Kansas City (Brentuximab Vedotin)

Withdrawn
  • T Cell Lymphoma
  • Brentuximab Vedotin
  • Kansas City, Kansas
    The University of Kansas Cancer Center, Westwood Campus
Feb 1, 2023

Dose Escalation and Safety Trial in Jerusalem (CART BCMA)

Recruiting
  • Dose Escalation and Safety
  • CART BCMA
  • Jerusalem, Israel
    Hadassah University Hospital
Jan 21, 2021

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin Trial in Chapel Hill, Winston-Salem (ATLCAR.CD30 cells)

Active, not recruiting
  • Hodgkin Disease
  • +8 more
  • ATLCAR.CD30 cells
  • Chapel Hill, North Carolina
  • +1 more
Mar 2, 2022

Lymphoma, T-Cell, Peripheral Trial in Czechia (Adcetris 50 MG Injection, Endoxan, Doxorubicin)

Not yet recruiting
  • Lymphoma, T-Cell, Peripheral
  • Adcetris 50 MG Injection
  • +4 more
  • Brno, Czechia
  • +6 more
Aug 26, 2021

Myasthenia Gravis, Generalized Trial in United States (Descartes-08)

Recruiting
  • Myasthenia Gravis, Generalized
  • Carlsbad, California
  • +8 more
Jan 27, 2023

Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

Not yet recruiting
  • Multiple Myeloma, Refractory
  • Multiple Myeloma in Relapse
  • Autologous CAR-T cell therapy expressing the BAFF-ligand.
  • Cleveland, Ohio
    University Hospitals Seidman Cancer Center
Jan 11, 2023

Multiple Myeloma Trial in Canada, United Kingdom, United States (GSK2857916)

Completed
Has Results
  • Multiple Myeloma
  • Boston, Massachusetts
  • +8 more
Jul 29, 2020

Multiple Myeloma Trial in Beijing, Suzhou (CAR-BCMA T Cells)

Recruiting
  • Multiple Myeloma
  • CAR-BCMA T Cells
  • Beijing, Beijing, China
  • +1 more
Jan 26, 2023

Multiple Myeloma Trial in Philadelphia (BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART

Active, not recruiting
  • Multiple Myeloma
  • BCMA CART + huCART19
  • +2 more
  • Philadelphia, Pennsylvania
    Univ. of Pennsylvania
Jul 11, 2022

Multiple Myeloma Trial in Worldwide (Elranatamab (PF-06863135))

Active, not recruiting
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Beverly Hills, California
  • +75 more
Oct 4, 2022

Multiple Myeloma Trial in Hangzhou, Wuhan (CART-BCMA)

Recruiting
  • Multiple Myeloma
  • Hangzhou, China
  • +1 more
Apr 23, 2022

Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma Trial (GEN3017)

Not yet recruiting
  • Classical Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • GEN3017
  • (no location specified)
Aug 25, 2023

Subjects Treated With ACTR T Cell Product

Terminated
  • B Cell Lymphomas
  • +3 more
  • ACTR T Cell Product
  • Gilbert, Arizona
  • +15 more
Oct 4, 2021

Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma Trial in United States (ALRN-6924)

Completed
  • Solid Tumor
  • +2 more
  • Birmingham, Alabama
  • +12 more
Jul 13, 2020

Multiple Myeloma, Relapse Multiple Myeloma Trial in Ramat Gan (CAR-BCMA)

Recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • CAR-BCMA
  • Ramat Gan, Israel
    Chaim Sheba Medical Center, Tel Hashomer
Feb 7, 2022

Multiple Myeloma Trial (Elranatamab (PF-06863135))

Temporarily not available
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • (no location specified)
Jul 15, 2022

Patients Undergoing CAR-T Cell Therapy (CAR_21_01)

Recruiting
  • CAR-T Therapy Complications
    • Bologna, Italy
      IRCC, University Hospital of Bologna
    Mar 18, 2022

    Multiple Myeloma Trial in United States (bb2121)

    Active, not recruiting
    • Multiple Myeloma
    • bb2121
    • Stanford, California
    • +8 more
    Dec 2, 2020

    Multiple Myeloma Trial in Houston (Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))

    Not yet recruiting
    • Multiple Myeloma
    • Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
    • Houston, Texas
      The University of Texas MD Anderson Cancer Center
    Jan 13, 2023

    Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Lenalidomide)

    Recruiting
    • Multiple Myeloma
    • Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
    • +7 more
    Jan 9, 2023